A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC
Véronique Dièras(Institut Curie), B Chevallier(Hôpital Paul-Brousse), Pierre Kerbrat(Institut Curie), I. Krakowski(Institut Curie), Henri Roché(Hôpital Paul-Brousse), JL Misset(Hôpital Paul-Brousse), M-A. Lentz(Hôpital Paul-Brousse), N. Azli(Hôpital Paul-Brousse), M Murawsky(Institut Curie), A. Riva(European Organisation for Research and Treatment of Cancer), P Pouillart(European Organisation for Research and Treatment of Cancer), P. Fumoleau(European Organisation for Research and Treatment of Cancer)
Cited by 84Open Access